Once again, FDA expands use of COVID-19 treatment without research to back it up
The U.S. Food and Drug Administration late Friday allowed the drug remdesivir to be used on all patients hospitalized with COVID-19, although no published research supports such widespread use.
The move, which comes less than a week after the agency approved use of convalescent plasma also with no published scientific support has fueled concerns the agency is yielding to political pressure.
"It seems to be a pattern of approval without science, without data, without evidence," said Dr. Eric Topol, vice president for research at Scripps Research in La Jolla, California and a national expert on the use of data in medical research.
In May, the FDA allowed remdesivir to be used for hospitalized patients who need oxygen, but not those sick enough to require ventilation. A government study published that month in the New England Journal of Medicine found those patients recovered faster than those who hadn't gotten the drug, though there was no evidence that it saved lives.
https://www.msn.com/en-us/health/medical/without-evidence-once-again-fda-expands-use-of-covid-19-treatment-without-research-to-back-it-up/ar-BB18ufb9?li=BBnb7Kz